To install click the Add extension button. That's it.

The source code for the WIKI 2 extension is being checked by specialists of the Mozilla Foundation, Google, and Apple. You could also do it yourself at any point in time.

4,5
Kelly Slayton
Congratulations on this excellent venture… what a great idea!
Alexander Grigorievskiy
I use WIKI 2 every day and almost forgot how the original Wikipedia looks like.
Live Statistics
English Articles
Improved in 24 Hours
Added in 24 Hours
What we do. Every page goes through several hundred of perfecting techniques; in live mode. Quite the same Wikipedia. Just better.
.
Leo
Newton
Brights
Milds

Sodium thiosulfate (medical use)

From Wikipedia, the free encyclopedia

Sodium thiosulfate
Sodium thiosulfate, structural formula
Clinical data
Trade namesPedmark, Pedmarqsi
AHFS/Drugs.comMicromedex Detailed Consumer Information
Routes of
administration
Intravenous
ATC code
  • None
Legal status
Legal status
Identifiers
  • Sodium thiosulfate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
Chemical and physical data
FormulaNa2O3S2
Molar mass158.10 g·mol−1
3D model (JSmol)
  • [O-]S(=O)(=S)[O-].[Na+].[Na+]
  • InChI=1S/2Na.H2O3S2/c;;1-5(2,3)4/h;;(H2,1,2,3,4)/q2*+1;/p-2
  • Key:AKHNMLFCWUSKQB-UHFFFAOYSA-L

Sodium thiosulfate, also spelled sodium thiosulphate, is used as a medication to treat cyanide poisoning, pityriasis versicolor, and to decrease side effects from cisplatin.[3][4][5] For cyanide poisoning, it is often used after the medication sodium nitrite and is typically only recommended for severe cases.[4][6] It is either given by injection into a vein or applied to the skin.[4]

Side effects may include vomiting, joint pain, mood changes, psychosis, and ringing in the ears.[5] Safety, however, has not been well studied.[7] It is unclear if use during pregnancy is safe for the baby.[5] Its use at the same time in the same intravenous line as hydroxocobalamin is not recommended.[6] In cyanide poisoning, sodium nitrite creates methemoglobinemia, which removes cyanide from the mitochondria.[6] Sodium thiosulfate then binds with cyanide, creating the nontoxic thiocyanate.[6]

Sodium thiosulfate came into medical use for cyanide poisoning in the 1930s.[8] It is on the World Health Organization's List of Essential Medicines.[9]

YouTube Encyclopedic

  • 1/5
    Views:
    1 425
    18 107
    447
    41 017
    6 286
  • Sodium Thiosulfate
  • Standardization of Thiosulfate using KIO3 and Released Iodine
  • Sodium Thiosulfate and Its Role in Calciphylaxis
  • Redox titration iodine and thiosulphate from www.ChemistryTuition.Net
  • poison and Antidote: sodium thiosulfate activated charcoal sodium nitrite। pharmaceutical inorganic।

Transcription

Medical uses

The main use of sodium thiosulfate is in cyanide poisoning and pityriasis versicolor.[4]

Cyanide poisoning

Sodium thiosulfate is a classical antidote to cyanide poisoning,[10] For this purpose it is used after the medication sodium nitrite and typically only recommended for severe cases.[4][6] It is given by injection into a vein.[4]

In this use, sodium nitrite creates methemoglobinemia which removes cyanide from mitochondria.[6] Sodium thiosulfate then serves as a sulfur donor for the conversion of cyanide to the nontoxic thiocyanate, catalyzed by the enzyme rhodanase. The thiocyanate is then safely excreted in the urine.[6][11]

There are concerns that sodium thiosulfate may not have a fast enough onset of action to be very useful for this use without the additional use of other agents.[11]

In cases with both cyanide poisoning and carbon monoxide poisoning, sodium thiosulfate by itself is recommended.[12]

Reducing hearing loss during chemotherapy

In September 2022, the U.S. Food and Drug Administration (FDA) approved sodium thiosulfate under the brand name Pedmark to lessen the risk of ototoxicity and hearing loss in infant, child, and adolescent cancer patients receiving the chemotherapy medication cisplatin.[3][13][14]

In the European Union, sodium thiosulfate (Pedmarqsi) is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in people aged 1 month to < 18 years of age with localized, non-metastatic, solid tumors.[2] The most common side effects include vomiting, nausea (feeling sick), hypernatremia (high blood levels of sodium), hypophosphatemia (low blood levels of phosphate) and hypokalemia (low blood levels of potassium).[2] Sodium thiosulfate (Pedmarqsi) was approved for medical use in the European Union in May 2023.[2]

Hemodialysis

There is a small amount of evidence supporting the use of sodium thiosulfate to counteract calciphylaxis, the calcification of blood vessels that may occur in hemodialysis patients with end-stage kidney disease.[15][16]

However, it has been claimed that this treatment may cause severe metabolic acidosis in some patients.[17][18]

Sodium thiosulfate has been observed to help in the treatment of a rare systemic fibrosis condition caused by gadolinium-based contrast media in patients with kidney failure.[19]

The compound can also be used to measure the volume of extracellular body fluid and the renal glomerular filtration rate.[20]

Fungal infections of the skin

Foot baths of sodium thiosulfate are used for prophylaxis of ringworm. It is also used as a topical antifungal agent for tinea versicolor (pityriasis versicolor), possibly in combination with salicylic acid;[21][22] and for other fungal infections of the skin.[23]

Side effects

Side effects may include vomiting, joint pain, mood changes, psychosis, and ringing in the ears.[5] Safety; however, has not been well studied.[7] It is unclear if use in pregnancy is safe for the baby.[5] Use at the same time in the same intravenous line as hydroxocobalamin is not recommended.[6]

History

Sodium thiosulfate came into medical use for cyanide poisoning in the 1930s.[24]

References

  1. ^ "Pedmark- sodium thiosulfate injection, solution". DailyMed. 30 September 2022. Archived from the original on 21 January 2023. Retrieved 21 January 2023.
  2. ^ a b c d "Pedmarqsi EPAR". European Medicines Agency. 2 June 2023. Archived from the original on 3 June 2023. Retrieved 2 June 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  3. ^ a b Orgel E, Villaluna D, Krailo MD, Esbenshade A, Sung L, Freyer DR (May 2022). "Sodium thiosulfate for prevention of cisplatin-induced hearing loss: updated survival from ACCL0431". The Lancet. Oncology. 23 (5): 570–572. doi:10.1016/S1470-2045(22)00155-3. PMC 9635495. PMID 35489339.
  4. ^ a b c d e f World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 66. hdl:10665/44053. ISBN 9789241547659.
  5. ^ a b c d e "Sodium thiosulfate Intravenous Advanced Patient Information - Drugs.com". www.drugs.com. Archived from the original on 18 January 2017. Retrieved 15 January 2017.
  6. ^ a b c d e f g h "Sodium Thiosulfate Solution for Injection - Summary of Product Characteristics (SPC) - (eMC)". www.medicines.org.uk. Archived from the original on 16 January 2017. Retrieved 15 January 2017.
  7. ^ a b "Sodium Thiosulfate Injection - FDA prescribing information, side effects and uses". www.drugs.com. Archived from the original on 18 January 2017. Retrieved 15 January 2017.
  8. ^ Dart, Richard C. (2004). Medical Toxicology. Lippincott Williams & Wilkins. p. 172. ISBN 9780781728454. Archived from the original on 2017-01-16.
  9. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  10. ^ "Toxicity, Cyanide: Overview". eMedicine. Archived from the original on 2008-12-29. Retrieved 2009-01-01.
  11. ^ a b Hall AH, Dart R, Bogdan G (June 2007). "Sodium thiosulfate or hydroxocobalamin for the empiric treatment of cyanide poisoning?". Annals of Emergency Medicine. 49 (6): 806–13. doi:10.1016/j.annemergmed.2006.09.021. PMID 17098327.
  12. ^ Baren JM (2008). Pediatric Emergency Medicine. Elsevier Health Sciences. p. 1018. ISBN 978-1416000877.
  13. ^ Winstead, Edward (October 6, 2022). "Sodium Thiosulfate Reduces Hearing Loss in Kids with Cancer". National Cancer Institute. Archived from the original on March 9, 2023. Retrieved March 9, 2023.
  14. ^ "FDA approves sodium thiosulfate to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors". U.S. Food and Drug Administration. 20 September 2022. Archived from the original on 9 March 2023. Retrieved 9 March 2023.
  15. ^ Auriemma M, Carbone A, Di Liberato L, Cupaiolo A, Caponio C, De Simone C, Tulli A, Bonomini M, Amerio P (October 2011). "Treatment of cutaneous calciphylaxis with sodium thiosulfate: two case reports and a review of the literature". American Journal of Clinical Dermatology. 12 (5): 339–46. doi:10.2165/11587060-000000000-00000. PMID 21834598. S2CID 28366905.
  16. ^ Cicone JS, Petronis JB, Embert CD, Spector DA (June 2004). "Successful treatment of calciphylaxis with intravenous sodium thiosulfate". American Journal of Kidney Diseases. 43 (6): 1104–8. doi:10.1053/j.ajkd.2004.03.018. PMID 15168392.
  17. ^ Berns JS (24 April 2012). "Sodium Thiosulfate and Acidosis: A Puzzle for Readers". Medscape. Archived from the original on 21 September 2015. Retrieved 16 February 2019.
  18. ^ Selk N, Rodby RA (Jan–Feb 2011). "Unexpectedly severe metabolic acidosis associated with sodium thiosulfate therapy in a patient with calcific uremic arteriolopathy". Seminars in Dialysis. 24 (1): 85–8. doi:10.1111/j.1525-139X.2011.00848.x. PMID 21338397. S2CID 23196149.
  19. ^ Yerram P, Saab G, Karuparthi PR, Hayden MR, Khanna R (March 2007). "Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure--role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate". Clinical Journal of the American Society of Nephrology. 2 (2): 258–63. doi:10.2215/CJN.03250906. PMID 17699422.
  20. ^ "Sodium thiosulfate" at Dorland's Medical Dictionary
  21. ^ Sunenshine PJ, Schwartz RA, Janniger CK (September 1998). "Tinea versicolor". International Journal of Dermatology. 37 (9): 648–55. doi:10.1046/j.1365-4362.1998.00441.x. PMID 9762812. S2CID 75657768.
  22. ^ Hu SW, Bigby M (October 2010). "Pityriasis versicolor: a systematic review of interventions". Archives of Dermatology. 146 (10): 1132–40. doi:10.1001/archdermatol.2010.259. PMID 20956647.
  23. ^ Rezabek GH, Friedman AD (May 1992). "Superficial fungal infections of the skin. Diagnosis and current treatment recommendations". Drugs. 43 (5): 674–82. doi:10.2165/00003495-199243050-00004. PMID 1379146. S2CID 46982698.
  24. ^ Dart RC (2004). Medical Toxicology. Lippincott Williams & Wilkins. p. 172. ISBN 9780781728454.
This page was last edited on 30 December 2023, at 12:33
Basis of this page is in Wikipedia. Text is available under the CC BY-SA 3.0 Unported License. Non-text media are available under their specified licenses. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. WIKI 2 is an independent company and has no affiliation with Wikimedia Foundation.